Zapata-Bonilla SA, López-Vargas R, Scherling-Ocampo AA, Morales-Leyte AL, García-Ilizaliturri L

Language: Spanish
References: 18
Page: 648-654
PDF size: 976.71 Kb.

ABSTRACT

A previously healthy, immunocompetent 67-year-old female presented with a one-month history of general symptoms, weight loss, night fevers, and bilateral lower extremity edema. On admission she had severe anemia, acute kidney injury, and multiple lymphadenopathies. An excisional biopsy of one of the axillary lymphadenopathies confirmed hyaline-vascular Castleman’s disease. This rare disease is a polyclonal lymphoproliferative disorder that affects the normal lymph node architecture. According to its location it can be divided in unicentric (localized) or multicentric disease; it can be further divided according to histopathology in hyaline-vascular or plasmatic cells variety. Clinical presentation relates more to histopathological variety than to centricity. Human herpes virus 8 is ubiquitous in this disease and, along with interleukin 6, plays an important role in pathogenesis and symptoms presentation. Surgery is the go-to treatment of localized disease, while systemic chemotherapy is the option in multicentric disease. Communication between the clinical and anatomopathological teams is crucial; lag in diagnosis can lead to futile investigations in search of other diseases and delay in treatment.

REFERENCES

1. Waterston A, Bower M. Fifty Years of Multicentric Castleman’s Disease. Acta Oncol. 2004; 43(8): 698-704.

2. Gantt S, Caspe C. Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment. Curr OpinInfect Dis. 2011,24:295-301.

3. Schulte KM, Talat N. Castleman´s Disease: a two compartment model of HHV8 infection. Nat Rev Clin Oncol. 2010;7:533-43.

4. El-Ozta HE, Kurzrock R. Castleman’s Disease: From Basic Mechanisms to Molecular Therapeutics. The Oncologist. 2011;16:497-511.

5. Nishimoto N, Kishimoto T. Interleukin 6: From bench to bedside. Nat Clin Pract Rheumatol. 2006;2:619-26.

6. Vinzio S, Ciarloni L, Schlienger JL, et al. Isolated microcytic anemia disclosing a unicentric Castleman disease: The interleukin-6/hepcidin pathway? Eur J Intern Med. 2008;19:367-9.

7. Temirbekov D, Mine Z, Ergelen R, et al. Case report Castleman disease of the parotid gland: An unusual entity. Otolaryngologiapolska. 2014;68:208-11.

8. Roca B. Castleman´s Disease. A review. AIDS rev. 2009;11:3-7.

9. Mu´´zes G, Sipos F, Csomor J, et al. Multicentric Castleman’s Disease: A Challenging Diagnosis. Pathol Oncol Res. 2013;19:345-51.

10. Bonekamp D, HortonK, Hruban R, et al. Castleman Disease: The Great Mimic. RadioGraphics. 2011;31:1793-807.

11. Dispenzieri A, Gertz MA. Treatment of Castleman’s disease. Curr Treat Options Oncol. 2005;6:255-66.

12. Berezne A, Agbalika F, Oksenhendler E. Failure of cidofovir in HIV-associated multicentric Castleman disease. Blood. 2004;103:4368-9.

13. Casper C, Nichols WG, Huang ML, et al. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood. 2004;103:1632-4.

14. Matsuyama M, Suzuki T, Tsuboi H, et al. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman’s disease. Intern Med. 2007;46:771-4.

15. Gérard L, Bérezné A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman’s disease: ANRS 117 CastlemaB Trial. J Clin Oncol. 2007;25:3350-6.

16. Motyckova G, Steensm DP. Why does my patient have Lymphadenopathy or Splenomegaly. Hematol Oncol Clin N Am. 2012;26:395-408.

17. Henry M, Kamat D. Integrating basic science into clinical teaching initiative series: approach to lymphadenopathy. Clin Pediatr. 2011;50(8):683-7.

18. Talat N, Schulte KM. Castleman’s Disease: Systematic Analysis of 416 Patients from the Literature. The Oncologist. 2011;16:1316-24.